DOCSLIB.ORG

Toxicology Reference Material

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

toxicology Toxicology covers a wide range of disciplines, including therapeutic drug monitoring, clinical toxicology, forensic toxicology (drug driving, criminal and coroners), drugs in sport and work place drug testing, as well as academia and research. Those working in the field have a professional interest in the detection and measurement of alcohol, drugs, poisons and their breakdown products in biological samples, together with the interpretation of these measurements. Abuse and misuse of drugs is one of the biggest problems facing our society today. Acute poisoning remains one of the commonest medical emergencies, accounting for 10-20% of hospital admissions for general medicine [Dargan & Jones, 2001]. Many offenders charged with violent crimes, or victims of violent crime may have been under the influence of drugs at the time the act was committed. The use of mind-altering drugs in the work place, or whilst in control of a motor vehicle places others in danger [Drummer, 2001]. Performance enhancing drugs in sport make for an uneven playing field and distract from the core ethic of sportsmanship. Patterns of drug abuse around the world are constantly evolving. They vary between geographies; from one country to another and even from region to region or population to population within countries. With a European presence, a wide reaching network of global customers and distributors, and activate participation in relevant professional societies, Chiron is well positioned to develop and deliver relevant, and current standards to meet customer demand in this challenging field. Chiron AS Stiklestadvn. 1 N-7041 Trondheim Norway Phone No.: +47 73 87 44 90 Fax No.: +47 73 87 44 99 E-mail: [email protected] Website: www.chiron.no Org. No.: NO 967 607 657 MVA CONTENTS SINGLE STANDARDS Analgesics (non-opioid) 1-4 Anaesthetics 4 Antibiotics 5 Anticancer 5 Anticoagulants 6 Anticonvulsants / Antiepileptics 6-7 Antidepressants 7-10 Antidiabetics 10 Antidyskinetic / Antimuscarinics / Antiparkinsonian 11 Antiemetics 11-12 Antifungals 12 Antihistamines 12-13 Anti-impotence 13 Anti-insomnia 13-14 Antimalarial 14 Antimicrobial 14 Antipsycotics 15-16 Antiretrovirals 16 Barbiturates 16 Benzodiazepines 16-20 Cannabinoids (Phyto) 21 Cardiac drugs 21-23 Cocaine and related compounds 23-25 Contrast media 25 Enzymes 25 Ephedrines 25-26 Ethanol and related compounds 26-28 Gastrointestinal drugs 28-29 Neurotransmitters 29 New psychoactive substances (NPS) 29-52 Amphetamines 29-31 Methamphetamines 31-33 Methylenedioxyphenethylamines 33 2C Phenethylamines (psychedelics) 34 Benzofuries (APBs and APDBs) 35 Indanes 35-36 Cathinones 36-38 Piperazines 38-39 Synthetic cannabinoids (Spice) 39-47 Designer forms of pharmaceuticals 47 Chiron AS Stiklestadvn. 1 N-7041 Trondheim Norway Phone No.: +47 73 87 44 90 Fax No.: +47 73 87 44 99 E-mail: [email protected] Website: www.chiron.no Org. No.: NO 967 607 657 MVA Quinazolinones 47 Methylphenidate related compounds 47-48 Other pharmaceuticals 48-49 Synthetic opioids 49 GHB and GBL 49 Diarylethylamines 50 Aryl cyclohexylamines 50 Tryptamines 50-51 Plant chemicals 51 Miscellaneous NPS 51-52 Nicotine and related compounds 52-53 Obstetrics 53 Opioids 53-58 Respiratory agents (including methylxanthines) 58-59 Steroids and Hormones 59-60 Vitamins 61 DRUG MIXTURES Amphetamines 62 Anticonvulsants / Antiepileptics 62 Antidepressants 63 Benzodiazepines 63 Cocaine 64 Congener alcohols 64 Opiates 64 Pharmaceutical residues 65 X-ray Contrast media 66 Z-Drugs 66 CALIBRATION SETS Amphetamines and Opiates 67 Benzoylecgonine and Benzodiazepines 67 THC-acid 67 Zopiclone, Zolpidem and 6-MAM 67 INDEX Alphabetical category index 68-89 Chiron AS Stiklestadvn. 1 N-7041 Trondheim Norway Phone No.: +47 73 87 44 90 Fax No.: +47 73 87 44 99 E-mail: [email protected] Website: www.chiron.no Org. No.: NO 967 607 657 MVA 1 SINGLE STANDARDS Analgesics (non-opioid) Catalogue No. Description (Abbreviation) Cas No. Concentration Solvent Volume Aceclofenac 9470.16-100-ME Aceclofenac 89796-99-6 100 µg/mL methanol 1 mL Aceclofenac Imp. I 9818.14-100-ME 15362-40-0 100 µg/mL methanol 1 mL (1-(2,6-Dichlorophenyl)indolin-2-one) Aceclofenac Imp. I 9818.14-10MG 15362-40-0 neat neat 10 mg (1-(2,6-Dichlorophenyl)indolin-2-one) Acetaminophen (Paracetamol) 2524.8-K-ME Acetaminophen 103-90-2 1000 µg/mL methanol 1 mL 2524.8-500MG Acetaminophen 103-90-2 neat neat 500 mg 9244.8-K-ME Acetaminophen-d3 (acetamide-d3 ) 60902-28-5 100 µg/mL methanol 1 mL 9244.8-10MG Acetaminophen-d3 (acetamide-d3 ) 60902-28-5 neat neat 10 mg 9244.8-100MG Acetaminophen-d3 (acetamide-d3 ) 60902-28-5 neat neat 100 mg 9245.8-100-ME Acetaminophen-d4 (phenyl-d4 ) 64315-36-2 100 µg/mL methanol 1 mL 9245.8-K-ME Acetaminophen-d4 (phenyl-d4 ) 64315-36-2 1000 µg/mL methanol 1 mL 9245.8-10MG Acetaminophen-d4 (phenyl-d4 ) 64315-36-2 neat neat 10 mg 9245.8-100MG Acetaminophen-d4 (phenyl-d4 ) 64315-36-2 neat neat 100 mg Acetaminophen Imp. B 2549.9-100-ME 1693-37-4 100 µg/mL methanol 1 mL (N -(4-Hydroxyphenyl)-propionamide) Acetaminophen Imp. B 2549.9-100MG 1693-37-4 neat neat 100 mg (N -(4-Hydroxyphenyl)-propionamide) Acetaminophen Imp. E 9821.8-100MG 99-93-4 neat neat 100 mg (1-(4-Hydroxyphenyl)ethanone) Acetaminophen Imp. F 2087.6-K-ME 100-02-7 1000 µg/mL methanol 1 mL (4-Nitrophenol) Acetaminophen Imp. F 2087.6-100MG 100-02-7 neat neat 100 mg (4-Nitrophenol) Acetaminophen Imp. H 2550.10-100-ME 2633-33-8 100 µg/mL methanol 1 mL (N,O- Diacetyl-4-aminophenol) Acetaminophen Imp. H 2550.10-100MG 2633-33-8 neat neat 100 mg (N,O- Diacetyl-4-aminophenol) Acetaminophen Imp. I 9221.8-100MG 118-93-4 neat neat 100 mg (1-(2-Hydroxyphenyl)ethanone, 2-Hydroxyacetophenone) Acetaminophen Imp. J 2512.8-K-ME 539-03-7 1000 µg/mL methanol 1 mL (4'-Chloroacetanilide) Acetaminophen Imp. J 2512.8-100MG 539-03-7 neat neat 100 mg (4'-Chloroacetanilide) Acetaminophen Imp. K 2519.6-K-ME 123-30-8 1000 µg/mL methanol 1 mL (4-Aminophenol) Acetaminophen Imp. K 2519.6-500MG 123-30-8 neat neat 500 mg (4-Aminophenol) Acetylsalicylic acid (Aspirin) 2513.9-K-ME Acetylsalicylic acid 50-78-2 1000 µg/mL methanol 1 mL 2513.9-100MG Acetylsalicylic acid 50-78-2 neat neat 100 mg 2513.9-500MG Acetylsalicylic acid 50-78-2 neat neat 500 mg Acetylsalicylic acid Imp. A 2514.7-K-ME 99-96-7 1000 µg/mL methanol 1 mL (4-Hydroxybenzoic acid) Acetylsalicylic acid Imp. A 2514.7-100MG 99-96-7 neat neat 100 mg (4-Hydroxybenzoic acid) Acetylsalicylic acid Imp. B 2539.8-K-ME 636-46-4 1000 µg/mL methanol 1 mL (4-Hydroxyisophthalic acid, 4-Hydroxybenzene-1,3-dicarboxylic acid) Acetylsalicylic acid Imp. B 2539.8-100MG 636-46-4 neat neat 100 mg (4-Hydroxyisophthalic acid, 4-Hydroxybenzene-1,3-dicarboxylic acid) Acetylsalicylic acid Imp. C 2515.7-K-ME 69-72-7 1000 µg/mL methanol 1 mL (Salicylic acid, 2-Hydroxybenzoic acid) Acetylsalicylic acid Imp. C 2515.7-500MG 69-72-7 neat neat 500 mg (Salicylic acid, 2-Hydroxybenzoic acid) Chiron AS Stiklestadvn. 1 N-7041 Trondheim Norway Phone No.: +47 73 87 44 90 Fax No.: +47 73 87 44 99 E-mail: [email protected] Website: www.chiron.no Org. No.: NO 967 607 657 MVA 2 Analgesics (non-opioid) continued… Catalogue No. Description (Abbreviation) Cas No. Concentration Solvent Volume Acetylsalicylic acid (Aspirin) Acetylsalicylic acid Imp. D 2516.16-100-ME 530-75-6 100 µg/mL methanol 1 mL (Acetylsalicylsalicylic acid) Acetylsalicylic acid Imp. D 2516.16-10MG 530-75-6 neat neat 10 mg (Acetylsalicylsalicylic acid) Acetylsalicylic acid Imp. D 2516.16-25MG 530-75-6 neat neat 25 mg (Acetylsalicylsalicylic acid) Acetylsalicylic acid Imp. D 2516.16-100MG 530-75-6 neat neat 100 mg (Acetylsalicylsalicylic acid) Acetylsalicylic acid Imp. F 2551.18-100-ME 1466-82-6 100 µg/mL methanol 1 mL (O- Acetylsalicylic anhydride) Acetylsalicylic acid Imp. F 2551.18-100MG 1466-82-6 neat neat 100 mg (O- Acetylsalicylic anhydride) 2710.14-100-ME 2-(2,4-Dihydroxybenzoyl)benzoic acid 2513-33-9 100 µg/mL methanol 1 mL Salicylic acid 2515.7-K-ME 69-72-7 1000 µg/mL methanol 1 mL (2-Hydroxybenzoic acid) Salicylic acid 2515.7-500MG 69-72-7 neat neat 500 mg (2-Hydroxybenzoic acid) 9242.7-K-ME Salicylic acid-d4 (3,4,5,6-d4 ) 78646-17-0 1000 µg/mL methanol 1 mL 9242.7-K-MEx10 Salicylic acid-d4 (3,4,5,6-d4 ) 78646-17-0 1000 µg/mL methanol 1 mL 9242.7-10MG Salicylic acid-d4 (3,4,5,6-d4 ) 78646-17-0 neat neat 10 mg 9243.7-K-ME Salicylic acid-d6 (perdeuterated) 285979-87-5 1000 µg/mL methanol 1 mL 9243.7-K-MEx10 Salicylic acid-d6 (perdeuterated) 285979-87-5 1000 µg/mL methanol 1 mL 9243.7-K-10MG Salicylic acid-d6 (perdeuterated) 285979-87-5 neat neat 10 mg Salicylic acid Imp. C 1427.6-K-ME 108-95-2 1000 µg/mL methanol 1 mL (Phenol) Salicylic acid Imp. C 1427.6-1G 108-95-2 neat neat 1 g (Phenol) 10258.7-1G 4-Aminosalicylic acid 65-49-6 neat neat 1 g Diclofenac 9467.14-K-ME Diclofenac 15307-86-5 1000 µg/mL methanol 1 mL 9321.14-K-ME Diclofenac-d4 (phenyl-d4 ) 153466-65-0 1000 µg/mL methanol 1 mL 9321.14-5MG Diclofenac-d4 (phenyl-d4 ) 153466-65-0 neat neat 5 mg Ethenzamide (2-Ethoxybenzamide) 10439.9-K-ME Ethenzamide 938-73-8 1000 µg /mL methanol 1 mL 10439.9-10MG Ethenzamide 938-73-8 neat neat 10 mg 10439.9-100MG Ethenzamide 938-73-8 neat neat 100 mg Etoricoxib (Arcoxia) 11414.18-10MG Etoricoxib 202409-33-4 neat neat 10 mg Hydroxychloroquine Hydroxychloroquine 11348.18-100MG 118-42-3 neat neat 100 mg (2-((4-(7-Chloroquinolin-4-ylamino)pentyl)(ethyl)amino)ethanol) Hydroxychloroquine sulfate 11347.18-100MG 2-((4-(7-Chloroquinolin-4-ylamino)pentyl)(ethyl)amino)ethanol 747-36-4 neat neat 100 mg sulfate Ibuprofen 2525.13-K-ME (± )- Ibuprofen 15687-27-1 1000 µg/mL methanol 1 mL 2525.13-100MG (± )- Ibuprofen 15687-27-1 neat neat 100 mg 2525.13-500MG (± )- Ibuprofen 15687-27-1 neat neat 500 mg 3851.13-K-ME (±)- Ibuprofen-d3 (α-methyl-d3 ) 121662-14-4 1000 µg/mL methanol 1 mL 3851.13-K-IO (±)- Ibuprofen-d3 (α-methyl-d3 ) 121662-14-4 1000 µg/mL isooctane 1 mL Ibuprofen Imp.
Recommended publications
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd

    Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd

    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
  • Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances 2017

    Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances 2017

    INTERNATIONAL NARCOTICS CONTROL BOARD Precursors and chemicals frequently used in the illicit manufacture of narcotic drugs and psychotropic substances 2017 EMBARGO Observe release date: Not to be published or broadcast before Thursday, 1 March 2018, at 1100 hours (CET) UNITED NATIONS CAUTION Reports published by the International Narcotics Control Board in 2017 The Report of the International Narcotics Control Board for 2017 (E/INCB/2017/1) is supplemented by the following reports: Narcotic Drugs: Estimated World Requirements for 2018—Statistics for 2016 (E/INCB/2017/2) Psychotropic Substances: Statistics for 2016—Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Substances of 1971 (E/INCB/2017/3) Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report of the International Narcotics Control Board for 2017 on the Implementation of Article 12 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2017/4) The updated lists of substances under international control, comprising narcotic drugs, psychotropic substances and substances frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, are contained in the latest editions of the annexes to the statistical forms (“Yellow List”, “Green List” and “Red List”), which are also issued by the Board. Contacting the International Narcotics Control Board The secretariat of the Board may be reached at the following address: Vienna International Centre Room E-1339 P.O. Box 500 1400 Vienna Austria In addition, the following may be used to contact the secretariat: Telephone: (+43-1) 26060 Fax: (+43-1) 26060-5867 or 26060-5868 Email: [email protected] The text of the present report is also available on the website of the Board (www.incb.org).
  • Effect of Sympathomimetic and Allied Amines on Temperature and Oxygen Consumption in Chickens by D

    Effect of Sympathomimetic and Allied Amines on Temperature and Oxygen Consumption in Chickens by D

    Br. J. Pharmac. Chemother. (1967), 31, 290-312. EFFECT OF SYMPATHOMIMETIC AND ALLIED AMINES ON TEMPERATURE AND OXYGEN CONSUMPTION IN CHICKENS BY D. J. ALLEN AND E. MARLEY From the Institute of Psychiatry, Maudsley Hospital, Denmark Hill, London (Received June 12, 1967) The sympathomimetic and allied amines can be divided into two main groups according to their chemical structure and to their effects in young chickens (Key & Marley, 1962; Dewhurst & Marley, 1965a, b). These groups are similar to those into which the amines are divided for their effects on smooth muscle (Fleckenstein & Burn, 1953; Burn & Rand, 1958; Maxwell, Povalski & Plummer, 1959; Vane, 1960; Marley, 1962; Trendelenburg, 1963) and this division clearly implies a fundamental difference in mode of action. In young chickens, catecholamines evoked sleep, whereas amphetamine-like amines and some tryptamines had the opposite effect and produced arousal (Key & Marley, 1962; Dewhurst & Marley, 1965a, b). The present experiments were made to determine the effects of these amines on temperature and oxygen consumption. Our results, a brief account of which was given to the Physiological Society (Allen & Marley, 1966), agree with those of Feldberg & Myers (1963, 1964a, 1965) who found that adrenaline and noradrenaline injected intraventricularly in cats lowered body temperature, whereas 5-hydroxytryptamine raised it. METHODS Animals Rhode Island Red pullets, 1-23 days old and weighing 30 to 150 g, and adult fowls of 1 to 2 kg were used, all from the same hatchery. For the first week after hatching they were kept in a cage thermostatically maintained at 33 to 340 C and for the subsequent 2 weeks at 29 to 310 C.
  • Free PDF Download

    Free PDF Download

    European Review for Medical and Pharmacological Sciences 2019; 23: 3-15 Use of cognitive enhancers: methylphenidate and analogs J. CARLIER1, R. GIORGETTI2, M.R. VARÌ3, F. PIRANI2, G. RICCI4, F.P. BUSARDÒ2 1Unit of Forensic Toxicology, Sapienza University of Rome, Rome, Italy 2Section of Legal Medicine, Universita Politecnica delle Marche, Ancona, Italy 3National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy 4School of Law, University of Camerino, Camerino, Italy Abstract. – OBJECTIVE: In the last decades, phenidate analogs should be undertaken to re- several cognitive-enhancing drugs have been duce the uprising threat, and education efforts sold onto the drug market. Methylphenidate and should be made among high-risk populations. analogs represent a sub-class of these new psy- choactive substances (NPS). We aimed to re- Key Words: view the use and misuse of methylphenidate and Cognitive enhancers, Methylphenidate, Ritalin, Eth- analogs, and the risk associated. Moreover, we ylphenidate, Methylphenidate analogs, New psycho- exhaustively reviewed the scientific data on the active substances. most recent methylphenidate analogs (methyl- phenidate and ethylphenidate excluded). MATERIALS AND METHODS: Literature Introduction search was performed on methylphenidate and analogs, using specialized search engines ac- cessing scientific databases. Additional reports Consumption of various pharmaceutical drugs were retrieved from international agencies, in- by healthy individuals in an attempt to improve stitutional websites, and drug user forums. cognitive faculties is on the rise, whether for aca- RESULTS: Methylphenidate/Ritalin has been demic or recreational purposes1. These substances used for decades to treat attention deficit disor- are stimulants that preferentially target the cate- ders and narcolepsy. More recently, it has been used as a cognitive enhancer and a recreation- cholamines of the prefrontal cortex of the brain to al drug.
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al

    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
  • Benzodiazepines: Uses and Risks Charlie Reznikoff, MD Hennepin Healthcare

    Benzodiazepines: Uses and Risks Charlie Reznikoff, MD Hennepin Healthcare

    Benzodiazepines: Uses and Risks Charlie Reznikoff, MD Hennepin healthcare 4/22/2020 Overview benzodiazepines • Examples of benzos and benzo like drugs • Indications for benzos • Pharmacology of benzos • Side effects and contraindications • Benzo withdrawal • Benzo tapers 12/06/2018 Sedative/Hypnotics • Benzodiazepines • Alcohol • Z-drugs (Benzo-like sleeping aids) • Barbiturates • GHB • Propofol • Some inhalants • Gabapentin? Pregabalin? 12/06/2018 Examples of benzodiazepines • Midazolam (Versed) • Triazolam (Halcion) • Alprazolam (Xanax) • Lorazepam (Ativan) • Temazepam (Restoril) • Oxazepam (Serax) • Clonazepam (Klonopin) • Diazepam (Valium) • Chlordiazepoxide (Librium) 4/22/2020 Sedatives: gaba stimulating drugs have incomplete “cross tolerance” 12/06/2018 Effects from sedative (Benzo) use • Euphoria/bliss • Suppresses seizures • Amnesia • Muscle relaxation • Clumsiness, visio-spatial impairment • Sleep inducing • Respiratory suppression • Anxiolysis/disinhibition 12/06/2018 Tolerance to benzo effects? • Effects quickly diminish with repeated use (weeks) • Euphoria/bliss • Suppresses seizures • Effects incompletely diminish with repeated use • Amnesia • Muscle relaxation • Clumsiness, visio-spatial impairment • Seep inducing • Durable effects with repeated use • Respiratory suppression • Anxiolysis/disinhibition 12/06/2018 If you understand this pharmacology you can figure out the rest... • Potency • 1 mg diazepam <<< 1 mg alprazolam • Duration of action • Half life differences • Onset of action • Euphoria, clinical utility in acute
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • The Toxicology Panel -17Th Nysam (Virtual) Conference 2021

    The Toxicology Panel -17Th Nysam (Virtual) Conference 2021

    THE TOXICOLOGY PANEL -17TH NYSAM (VIRTUAL) CONFERENCE 2021 MODERATOR: TIMOTHY J. WIEGAND, MD, FACMT, FAACT, DFASAM JoAn Laes, MD Addiction Medicine Faculty Hennepin County Medical Center, Minneapolis, MN Lewis Nelson, MD, FACMT Chair, Department of Emergency Medicine, Rutgers New Jersey Medical School Jeanmarie Perrone, MD Director of Division of Medical Toxicology & Penn Center PANELISTS for Addiction Medicine and Policy Ross Sullivan, MD Director SUNY Upstate Emergency Bridge Clinic & Medical Director Helio Health, Syracuse, NY Paul Wax, MD, FACMT Executive Director the American College of Medical Toxicology CONFLICT OF NONE OF OUR SPEAKERS HAVE ANY CONFLICTS OF INTEREST INTEREST TO DISCLOSE A 27 year-old M with history of opioid and sedative use disorder had been doing well in an outpatient treatment program with mix of counseling and treatment with buprenorphine/naloxone. CASE 1 He entered the program about 9 months prior after a 28 day combined detoxification/inpatient facility stay where he was transitioned from heroin/fentanyl (“10 bags/day”) to the buprenorphine and “detoxified” from 2-4 mg alprazolam and/or 2-4 mg clonazepam daily. CASE 1 About 9 months into the program he is found sleeping at work by his boss and when awoke he is slurring his speech and has trouble walking. This was a job he’d lost prior to treatment but they had let him back in 3 months after starting in treatment after he demonstrated sobriety –he worked with his father in a recycling plant coordinating large shipments and sometimes picking up materials using heavy equipment and other machinery. He lives with his parents and they are quite upset about the incident but he states, “I wasn’t using I was just tired!” CASE 1 The parents communicate with his counselor and he is brought in for a urine drug test –which initially tests positive for benzodiazepines but the confirmation is negative.
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs

    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs

    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Advisory Council on the Misuse of Drugs

    Advisory Council on the Misuse of Drugs

    ACMD Advisory Council on the Misuse of Drugs Chair: Dr Owen Bowden-Jones Secretary: Zahi Sulaiman 1st Floor (NE), Peel Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 1121 [email protected] Sarah Newton MP Minister for Vulnerability, Safeguarding and Countering Extremism Home Office 2 Marsham Street London SW1P 4DF 10 March 2017 Dear Minister, RE: Further advice on methylphenidate-related NPS In February 2016, my predecessor Professor Les Iversen wrote to the then minister for Preventing Abuse, Exploitation and Crime, requesting that the Temporary Class Drug Order (TCDO) on seven methylphenidate-related Novel Psychoactive Substances be re-laid for a further 12 months. This TCDO was re-laid until June 2017, to allow the Advisory Council on the Misuse of Drugs (ACMD) more time to collect the evidence required to provide further advice for full control under the Misuse of Drugs Act 1971. The ACMD believes that the TCDO has been effective in reducing the prevalence of these substances and that the TCDO level of control was proportionate in the interim. I am now pleased to present to you the ACMD’s further advice on this matter in the enclosed report. The ACMD’s recommendation for full control applies to the seven substances currently controlled under the TCDO and extends to an additional five closely-related substances. These five similar substances have subsequently appeared on markets following the TCDO and are included in this advice due to their potential for similar harms. Recommendation The ACMD recommends that the